Creative Planning’s Neuropace NPCE Stock Holding History

Creative Planning’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,867	Closed	-$306K	–	3762
2025 Q1	$306K	Buy	+24,867	New	+$311K	﹤0.01%	2739

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Creative Planning's NPCE Position: Q2 2025 in Review

Creative Planning sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 24,867 shares — an estimated $306K sold.

Creative Planning first reported a position in NPCE in Q1 2025 and held it in 1 quarter. The position peaked at $306K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

Creative Planning reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
Creative Planning sold 24,867 Neuropace shares in Q2 2025, an estimated $306K.
Creative Planning first reported a position in Neuropace in Q1 2025 and held it in 1 quarter.
Creative Planning's Neuropace position peaked at $306K in Q1 2025.
98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Creative Planning's 13F filing for Q2 2025, filed 8 Aug 2025.